skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Nome da Publicação: Annals Of Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

Kang, Y.-K. ; Kang, W.-K. ; Shin, D.-B. ; Chen, J. ; Xiong, J. ; Wang, J. ; Lichinitser, M. ; Guan, Z. ; Khasanov, R. ; Zheng, L. ; Philco-Salas, M. ; Suarez, T. ; Santamaria, J. ; Forster, G. ; McCloud, P. I.

Annals of oncology, 2009-04, Vol.20 (4), p.666-673 [Periódico revisado por pares]

Oxford: Oxford University Press

Texto completo disponível

Citações Citado por
2
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

Boku, N. ; Ryu, M.-H. ; Kato, K. ; Chung, H.C. ; Minashi, K. ; Lee, K.-W. ; Cho, H. ; Kang, W.K. ; Komatsu, Y. ; Tsuda, M. ; Yamaguchi, K. ; Hara, H. ; Fumita, S. ; Azuma, M. ; Chen, L.-T. ; Kang, Y.-K.

Annals of oncology, 2019-02, Vol.30 (2), p.250-258 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer

Okines, A.F.C. ; Norman, A.R. ; McCloud, P. ; Kang, Y.-K. ; Cunningham, D.

Annals of oncology, 2009-09, Vol.20 (9), p.1529-1534 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma

Kang, Y.-K. ; Yau, T. ; Park, J.-W. ; Lim, H.Y. ; Lee, T.-Y. ; Obi, S. ; Chan, S.L. ; Qin, S.K. ; Kim, R.D. ; Casey, M. ; Chen, C. ; Bhattacharyya, H. ; Williams, J.A. ; Valota, O. ; Chakrabarti, D. ; Kudo, M.

Annals of oncology, 2015-12, Vol.26 (12), p.2457-2463 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data
A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data

Satoh, T. ; Chen, L.-T. ; Kang, Y.-K. ; Chao, Y. ; Kato, K. ; Chung, H.C. ; Chen, J.-S. ; Muro, K. ; Kang, W.K. ; Yoshikawa, T. ; Oh, S.C. ; Tamura, T. ; Lee, K.-W. ; Boku, N.

Annals of oncology, 2018-10, Vol.29, p.viii206-viii206 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)

Ryu, M.-H. ; Baba, E. ; Lee, K.H. ; Park, Y.I. ; Boku, N. ; Hyodo, I. ; Nam, B.-H. ; Esaki, T. ; Yoo, C. ; Ryoo, B.-Y. ; Song, E.-K. ; Cho, S.-H. ; Kang, W.K. ; Yang, S.H. ; Zang, D.Y. ; Shin, D.B. ; Park, S.R. ; Shinozaki, K. ; Takano, T. ; Kang, Y.-K.

Annals of oncology, 2015-10, Vol.26 (10), p.2097-2101 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy

Kang, Y.-K. ; Ryu, M.-H. ; Park, S.H. ; Kim, J.G. ; Kim, J.W. ; Cho, S.-H. ; Park, Y.-I. ; Park, S.R. ; Rha, S.Y. ; Kang, M.J. ; Cho, J.Y. ; Kang, S.Y. ; Roh, S.Y. ; Ryoo, B.-Y. ; Nam, B.-H. ; Jo, Y.-W. ; Yoon, K.-E. ; Oh, S.C.

Annals of oncology, 2018-05, Vol.29 (5), p.1220-1226 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
Material Type:
Artigo 		Adicionar ao Meu Espaço

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

Demetri, G.D. ; Antonescu, C.R. ; Bjerkehagen, B. ; Bovée, J.V.M.G. ; Boye, K. ; Chacón, M. ; Dei Tos, A.P. ; Desai, J. ; Fletcher, J.A. ; Gelderblom, H. ; George, S. ; Gronchi, A. ; Haas, R.L. ; Hindi, N. ; Hohenberger, P. ; Joensuu, H. ; Jones, R.L. ; Judson, I. ; Kang, Y.-K. ; Kawai, A. ; Lazar, A.J. ; Le Cesne, A. ; Maestro, R. ; Maki, R.G. ; Martín, J. ; Patel, S. ; Penault-Llorca, F. ; Premanand Raut, C. ; Rutkowski, P. ; Safwat, A. ; Sbaraglia, M. ; Schaefer, I.-M. ; Shen, L. ; Serrano, C. ; Schöffski, P. ; Stacchiotti, S. ; Sundby Hall, K. ; Tap, W.D. ; Thomas, D.M. ; Trent, J. ; Valverde, C. ; van der Graaf, W.T.A. ; von Mehren, M. ; Wagner, A. ; Wardelmann, E. ; Naito, Y. ; Zalcberg, J. ; Blay, J.-Y.

Annals of oncology, 2020-11, Vol.31 (11), p.1506-1517 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

Gazzah, A. ; Bedard, P.L. ; Hierro, C. ; Kang, Y.-K. ; Abdul Razak, A. ; Ryu, M.-H. ; Demers, B. ; Fagniez, N. ; Henry, C. ; Hospitel, M. ; Soria, J.-C. ; Tabernero, J.

Annals of oncology, 2022-04, Vol.33 (4), p.416-425 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

Roy, A.C. ; Park, S.R. ; Cunningham, D. ; Kang, Y.K. ; Chao, Y. ; Chen, L.T. ; Rees, C. ; Lim, H.Y. ; Tabernero, J. ; Ramos, F.J. ; Kujundzic, M. ; Cardic, M.B. ; Yeh, C.G. ; de Gramont, A.

Annals of oncology, 2013-06, Vol.24 (6), p.1567-1573 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (283)

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.